Novo Nordisk A/S and its subsidiaries research, develop, manufacture, and distribute pharmaceutical products. It operates in two segments: Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes Care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas, while the Rare Disease segment offers products for rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides the NovoPen 6 and NovoPen Echo Plus smart insulin pens, the Dose Check insulin dose guidance application, growth hormone pens and injection needles, and the Wegovy pill, an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk CEO Mike Doustdar Resets Obesity Strategy With "Novo Way"
Novo Nordisk CEO Mike Doustdar is resetting the drugmaker's culture and competitive focus under a new "Novo Way" emphasizing customer focus, competitiveness, clarity and care, as the company rebrands to the day-to-day name "Novo" after losing ground to Eli Lilly in obesity drugs. Novo pioneered the modern obesity-drug market with Wegovy in the U.S. in 2021, but Eli Lilly has since gained ground with Zepbound and more aggressive consumer-focused commercialization. Novo has moved into oral obesity treatment with its Wegovy pill, and expects oral drugs to account for more than one-third of GLP-1 obesity-treatment use by 2030; analysts expect the U.S. obesity-treatment market to exceed $100 billion annually by 2030. Novo's Wegovy pill had captured roughly 90% of the U.S. oral-obesity market as of August, although Lilly subsequently said its Foundayo treatment had already captured more than 30% of new U.S. oral-treatment patients. Doustdar's message is that Novo must operate differently to defend and expand its position, and the company's September 21 capital-markets day should show investors how the "Novo Way" will translate into stronger competitive performance.
Novo Nordisk's once-weekly Sogroya wins positive CHMP opinion for idiopathic short stature in children
Novo Nordisk has received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency recommending once-weekly Sogroya, or somapacitan, for children in Europe living with idiopathic short stature with persistent growth disturbance. If approved, Sogroya would be the first and only growth hormone treatment approved for idiopathic short stature in the EU, a condition that affects up to 3% of children worldwide. The opinion follows the CHMP's May 2026 recommendation of Sogroya for short stature in children born small for gestational age and with Noonan Syndrome, and the decision now passes to the European Commission, whose ruling on marketing authorisation covering all three indications is expected later this year. The recommendation was supported by data from the REAL8 phase 3 basket trial, in which once-weekly Sogroya was non-inferior to once-daily growth hormone treatment for mean annualised height velocity at Week 52 in children with idiopathic short stature, those born small for gestational age and those with Noonan Syndrome. Sogroya is already authorised in the EU for growth hormone deficiency in adults since 31 March 2021 and in children aged 3 years and older since 24 July 2023.
Novo Nordisk Halts Two More Ziltivekimab Heart Trials After July Failure
Novo Nordisk A/S halted two additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker's efforts to diversify beyond its blockbuster obesity and diabetes franchise. The move follows a July disclosure that ziltivekimab failed to reduce major adverse cardiovascular events in a late-stage trial. An independent data monitoring committee found a low likelihood that the two additional heart-failure studies would produce a different result from that earlier failure, prompting Novo to end them ahead of schedule. Novo will continue testing ziltivekimab in patients recovering from a heart attack, with results expected in the first half of 2027. The company's oral Wegovy pill has already generated more than 2 million prescriptions shortly after its January 2026 launch, as Novo competes with Eli Lilly in the oral GLP-1 market.
Ascendis Pharma to Regain TransCon Metabolic and Cardiovascular Rights After Novo Nordisk Collaboration Ends
Ascendis Pharma A/S announced on September 14 that it will regain exclusive rights to develop, manufacture, and commercialize TransCon products in metabolic and cardiovascular diseases following the termination of its collaboration with Novo Nordisk A/S. The returned rights include once-monthly TransCon Semaglutide, an investigational long-acting prodrug of semaglutide intended for obesity and type 2 diabetes, and neither party will have continuing financial obligations to the other. Once the termination becomes effective and the rights revert, management plans to initiate multiple programs across rare and large indications, though the announcement did not disclose a development budget or a clinical-start date for the monthly candidate. Ascendis brings three consecutive approved products from its product-development approach, but the company must still establish sustained drug exposure, acceptable safety and meaningful efficacy at the intended dosing interval, and the announcement contained no new human efficacy or safety results for TransCon Semaglutide. Insider Monkey's database showed 49 hedge funds holding Ascendis Pharma A/S at the end of 2Q2026, up from 47 funds three months earlier.
Novo Nordisk's Frehemgo wins EMA panel backing for hemophilia A
A European Medicines Agency panel has recommended approval of Frehemgo, Novo Nordisk's injectable treatment for hemophilia A, moving the Danish drugmaker closer to another commercial opportunity outside its diabetes and obesity franchise. The recommendation covers adults and children, including patients with or without inhibitors, and follows results from Novo's FRONTIER clinical program, in which Frehemgo reduced annualized bleeding rates compared with previous clotting-factor preventive treatments and therapies given when bleeding occurred. Novo plans to sell Frehemgo in a single-use, prefilled pen with dosing options ranging from once weekly to once monthly, offering patients more flexibility. The European Commission still needs to give final approval, but Novo is already preparing for commercialization and expects to introduce Frehemgo in a selected European market during the fourth quarter, followed by a broader European Union rollout early next year. The next catalyst is European Commission approval and whether Novo can begin that first launch before year-end.
Low-Dose GLP-1 Weight-Loss Drugs Still Work, Study Finds
A new study reported by Reuters on August 31, 2026 found that patients who stay on the lowest starter doses of GLP-1 weight-loss drugs still lose weight, though far less than at full recommended doses, and experience less nausea. Patients on Eli Lilly's low-dose tirzepatide lost an average of 5.5% of their body weight over a year, versus 2.2% for Novo Nordisk's low-dose semaglutide, compared with 20.2% and 13.7% respectively at the higher, manufacturer-recommended doses seen in earlier trials. The low-dose tirzepatide group also showed higher rates of certain side effects, including constipation and muscle cramps, than the low-dose semaglutide group. The findings support an overall patient base for both companies, since many patients struggle with cost, tolerability, supply, or their personal weight-loss goals, and evidence that lower doses still work could help more patients remain on treatment. However, low-dose treatment could reduce revenue per patient if more users avoid higher maintenance doses, and the study highlights a difficult trade-off between efficacy and tolerability as competition intensifies.
Novo Nordisk Expands AI Push With Anthropic Drug Discovery Deal
Novo Nordisk is expanding its artificial intelligence capabilities through a new collaboration with Anthropic aimed at accelerating drug discovery and the development of new medicines. Under the agreement, Novo will use Anthropic's models and Claude Science across selected research and development workflows, while also applying Anthropic's frontier models to strengthen AI-driven software development. The collaboration will focus on drug discovery challenges identified by Novo's scientists and computational teams, with Claude Science initially tested in selected R&D applications involving biological reasoning. The deal adds to Novo's growing network of technology partnerships, following a strategic partnership with OpenAI in April 2026 and an August partnership with Amazon Web Services, which was named its preferred cloud provider and strategic AI partner and included a London co-innovation hub focused on drug discovery. Novo shares have lost 18% year to date against the industry's 10.9% growth, and the company currently carries a Zacks Rank #3 (Hold).
DelveInsight Forecasts PNH Market to Reach USD 1.5 Billion by 2036 on Five Emerging Therapies
DelveInsight estimates the paroxysmal nocturnal hemoglobinuria market across the seven major markets was valued at approximately USD 1.5 billion in 2025 and is projected to expand at a CAGR of 7.1% through 2036, driven by novel complement-targeted therapies and rising diagnosis. The seven major markets comprise the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Five emerging therapies are highlighted as poised to reshape the market: Regeneron Pharmaceuticals' Pozelimab plus Cemdisiran, Novo Nordisk's Zaltenibart, also known as OMS906, NovelMed Therapeutics' Ruxoprubart, also known as NM8074, Kira Pharmaceuticals' KP104, and NovelMed Therapeutics' NM5072. Aparna Thakur, Project Manager of Forecasting and Analytics at DelveInsight, said Pozelimab is expected to generate the highest revenue in the 7MM, followed by Zaltenibart, which demonstrated strong efficacy in a Phase II study in PNH patients with suboptimal responses to ravulizumab. Regeneron has said Phase III results for the pozelimab-cemdisiran combination in PNH are anticipated in the fourth quarter of 2026 or the first quarter of 2027, while Novo Nordisk gained exclusive worldwide rights to zaltenibart through an asset purchase and license agreement with Omeros Corporation announced in November 2025.
Orbis Medicines and Novo Nordisk Sign Up to USD 1.4 Billion Drug Discovery Deal
Orbis Medicines has entered a strategic collaboration and license agreement with Novo Nordisk to discover and develop next-generation oral macrocycle therapeutics for cardiometabolic diseases. Under the terms, Orbis Medicines is eligible to receive up to USD 1.4 billion in upfront and potential development and commercial milestone payments, plus tiered royalties on future product sales, and Novo will also make a strategic investment in Orbis Medicines. The collaboration will use Orbis Medicines' proprietary nGen platform, which integrates generative AI with high-throughput synthesis to design orally bioavailable macrocycles called nCycles. Morten Graugaard, chief executive officer of Orbis Medicines, said the partnership could unlock a new generation of oral medicines for cardiometabolic diseases, while Brian Vandahl, senior vice president of Therapeutics Discovery at Novo, said the collaboration could expand the possibilities of macrocycle therapeutics. Orbis Medicines, based in Copenhagen, Denmark and Lausanne, Switzerland, has raised EUR 116 million in venture funding to date, including a EUR 90 million Series A round led by NEA.
Asia Plus highlights NOVOB80 as Novo Nordisk teams up with Anthropic to use AI to elevate R&D, target price 1.62 baht
Asia Plus Securities said in an analysis that Novo Nordisk A/S is advancing its collaboration with Anthropic to apply artificial intelligence, or AI, in its research and development processes, including the discovery and development of new drugs. It plans to use Claude Science and Agentic AI technology to improve data analysis efficiency, shorten research timelines, and accelerate the process of bringing products to market. The collaboration reflects Novo Nordisk's strategy to elevate the organization into a more AI-driven healthcare company, alongside its emphasis on data governance and human oversight. The research team holds a positive view of this collaboration, assessing that it will help raise R&D efficiency and improve the quality of drug products in development, which is a key factor amid intensifying competition in the obesity and diabetes drug market, especially competition with Eli Lilly. However, the research team assesses that the positive effect on the share price in the short term remains limited, since the project is still in its early stages and the impact on revenue and profit cannot yet be clearly evaluated. As for Novo Nordisk shares, or NOVOB DC, they recently stood at 272.60 Danish kroner, while the Depositary Receipt, or NOVOB80, stood at 1.42 baht, using a reference exchange rate of 5.12 baht per Danish krone and a conversion ratio of 1 underlying share per 1,000 DR units. The research team gives a buy recommendation, with a one-year target price for NOVOB DC of 315.89 Danish kroner, equivalent to a target price for NOVOB80 of 1.62 baht. On the technical view for NOVOB80, the price is expected to move sideways, with support at 1.30-1.34 baht and resistance at 1.50-1.58 baht.
Novo Nordisk Adopts Anthropic's Claude for Drug Research
Novo Nordisk has brought Anthropic's Claude into its drug-research workflow, Reuters reported Wednesday, with the U.S. depositary shares trading at $42.125. The diabetes-and-obesity pharmaceutical leader will begin by testing Claude Science on selected scientific questions while also deploying Anthropic models for software-development work. The partnership is aimed at speed rather than AI headlines, with Novo and Anthropic seeking to sharpen biological reasoning and compress the time researchers spend moving from an idea to an actionable scientific decision. No contract value, exclusivity terms, development milestones or quantified savings were disclosed, leaving execution as the real story. Novo produced DKK33.39 billion of adjusted operating profit from DKK78.49 billion of second-quarter sales, implying an adjusted operating margin of roughly 42.5%, while the shares sit at $42.125 against a GF Value estimate of $105.13, leaving the market price 59.93% below that benchmark.
Novo Nordisk Shares Fall 2% After Rebrand as Analyst Keeps Hold Rating
Novo Nordisk shares fell 2% on Tuesday even after the drugmaker introduced a new brand identity and updated its corporate culture, as an analyst said the changes may need to be supported by a broader strategy. BMO Capital analyst Evan Seigerman kept a Hold rating and a $47 price target on the shares, implying about 8% upside from current levels. The company began using the name Novo in its branding and introduced The Novo Way, a culture centered on patients and consumers, while its legal corporate name remains Novo Nordisk A/S. Seigerman viewed the rollout of the Wegovy pill as a positive development but said the company still needs to show how it can maintain growth over the next decade, and he pointed to pressure from Eli Lilly in diabetes and obesity treatments as a concern.
Lilly's Foundayo Captures Over 30% of New U.S. Oral Weight-Loss Patients
Eli Lilly and Company says its newly launched oral obesity drug Foundayo has captured more than 30% of new U.S. patients starting oral weight-loss medicines, a notable early gain against Novo Nordisk's Wegovy pill. Reuters reports that Wegovy initially held roughly 90% of the oral market, making Lilly's rapid share capture an important sign that the oral GLP-1 market is becoming a two-player competition rather than a Novo-dominated segment. The broader U.S. obesity-drug market is expected to exceed $100 billion annually by 2030, with oral treatments potentially accounting for more than one-third of GLP-1 use. Foundayo was only launched in the U.S. in April 2026, starting at $149 per month for self-pay patients and as little as $25 for eligible commercially insured patients, while Medicare beneficiaries can access it through the GLP-1 Bridge program at $50 per month. Lilly's SEC filing says Mounjaro and Zepbound already represented 65% of its revenue in the first six months of 2026, highlighting both the importance of the incretin franchise and the opportunity for Foundayo to broaden Lilly's cardiometabolic revenue base.
Novo Nordisk Rebrands as "Novo" in Strategic Reset as Lilly Pressure Mounts
Novo Nordisk A/S is rebranding its day-to-day identity as "Novo" and launching a cultural reset aimed at regaining competitiveness in the obesity-drug market as pressure from Eli Lilly intensifies, according to Reuters. The move precedes the company's September 21 Capital Markets Day, where it plans to unveil new strategic ambitions. Novo generated DKK 309.1 billion of 2025 sales and DKK 127.7 billion of operating profit, with obesity-care sales rising 31% at constant exchange rates to DKK 82.3 billion, though its diabetes value-market share fell 3.6 percentage points to 30.1% and it spent around DKK 8 billion on its transformation in 2025. Novo remains the global obesity-market leader with a 59.6% branded-volume share in 2025, but Lilly is narrowing the gap, with Q2 2026 Mounjaro sales jumping 91% to $9.94 billion and Zepbound generating $4.93 billion, while Novo's oral Wegovy sales of $497 million came in below expectations. Lilly subsequently raised its 2026 revenue forecast to $85 billion-$87 billion, and Novo faces expectations of a 5%-13% decline in 2026 sales amid pricing pressure.
Eli Lilly and Novo Nordisk paid over 270,000 doctors to promote GLP-1 drugs, one receiving $1M
Eli Lilly and Novo Nordisk have paid more than 270,000 doctors since 2018 to promote GLP-1 weight-loss drugs through medical boards, research, educational seminars and direct outreach to fellow physicians, according to research by the Washington Post. One of those doctors, family physician Dr. Carlos Campos, has received $1 million from drug companies for his GLP-1 promotional work, traveling across the U.S. from his practice in New Braunfels, Texas. Novo Nordisk told Moneywise it follows the highest ethical standards and all legal and regulatory requirements in sharing scientific information with healthcare professionals. Critics such as Georgetown University Medical Center's Dr. Adriane Fugh-Berman warn that industry-sponsored continuing medical education courses, which are free to physicians and often led by paid physician-educators, spread drug company marketing messages throughout the profession. A recent Gallup poll found 90% of Americans are aware of GLP-1s and 11% of U.S. adults have prescriptions for weight loss, up from 3% two years ago, while an estimated 30 million Americans will be on GLP-1s by 2030 and the global market could be worth $200 billion.
Novo Nordisk Rebrands as Novo in Consumer Health Push
Novo Nordisk has rebranded to "Novo" as part of a shift toward a more consumer-focused healthcare identity. The group is introducing a new corporate culture intended to support its obesity and diabetes franchises in increasingly crowded markets, with management positioning the rebrand as a move beyond traditional pharmaceuticals toward broader consumer-facing health solutions. Novo Nordisk operates as a large pharmaceuticals group focused on researching, manufacturing, and distributing treatments, including obesity and diabetes therapies, with a market value of about DKK1.2 trillion. The company's Narrative points toward a DKK310 fair value for Novo Nordisk, built on the idea that GLP-1 obesity and diabetes drugs can support long-term earnings even as pricing pressure and competition from Eli Lilly and others increase. The rebrand leans into that expansion theme, though the bear case remains visible, since a culture built around "customer obsession" and faster decision-making must operate within flagged risks on pricing, generic competition and high manufacturing spend.
Novo Nordisk Wins China Approval for Wegovy in MASH
Novo Nordisk has received approval in China for Wegovy to treat metabolic dysfunction-associated steatohepatitis, or MASH, making it the first GLP-1 receptor agonist approved in the country for the liver disease. The approval expands Wegovy's potential beyond weight management and cardiovascular benefits into another major condition linked to obesity, and Reuters noted that Novo sees the decision as further evidence of the drug's broader role in treating complications associated with obesity. The move gives Novo an early advantage in China's MASH market while competitors work on developing or securing approval for similar treatments, and it supports the case for Wegovy as a broader metabolic-health treatment rather than simply a weight-loss drug. Still, the financial impact may take time to show: the Wall Street Journal reported that Novo's GLP-1 sales in China declined 8% in 2025 amid intense competition, and nearly 250 Chinese GLP-1 treatments are reportedly in development, with lower operating costs and limited insurance coverage adding pressure on pricing. Novo has also faced setbacks elsewhere, including the termination of two additional cardiovascular trials for ziltivekimab, making Wegovy and related products even more important to its future growth.
Novo Nordisk Repurchases 18.3 Million B Shares Under DKK 11.2 Billion Tranche
Novo Nordisk has repurchased 18,325,000 B shares for a total transaction value of DKK 5,526,186,488 under the share repurchase programme it initiated on 6 May 2026. That programme, running from 6 May 2026 to 1 February 2027, allows repurchases of up to DKK 11,200,000,010.45 and is itself part of the company's overall share repurchase programme of up to DKK 15 billion to be executed over the 12-month period beginning 4 February 2026. In the latest week, Novo Nordisk bought 210,000 B shares on each of 7, 8, 9, 10 and 11 September 2026, at average purchase prices of 297.98, 295.53, 289.37, 288.08 and 278.62 Danish kroner respectively. With these transactions, Novo Nordisk holds 47,124,876 B shares as treasury shares, equal to 1.1% of its share capital, out of a total of 4,465,000,000 A and B shares including treasury shares. Since 4 February 2026, the company has repurchased a total of 33,084,179 B shares at an average price of DKK 281.89 per B share, a transaction value of DKK 9,326,186,478.
Novo Nordisk Earns Zacks Rank #3 as Estimates Edge Higher
Novo Nordisk holds a Zacks Rank #3 (Hold), with consensus earnings estimates for the current quarter, fiscal year and next fiscal year all revised slightly higher over the past 30 days. The current-quarter consensus estimate stands at $0.80 per share, a year-over-year change of -21.6%, and has moved +0.3% over the last 30 days. For the current fiscal year the consensus estimate of $3.45 points to a change of -12.9% from the prior year and has risen +1.1% over the past month, while the next fiscal year's estimate of $3.42 indicates a change of -0.9% and has increased +1.3% over the same period. Consensus sales estimates are $11.47 billion for the current quarter, $45.78 billion for the current fiscal year and $46.38 billion for the next fiscal year, indicating year-over-year changes of -2.4%, -2.1% and +1.3% respectively. In the last reported quarter Novo Nordisk posted revenues of $12.21 billion, up +4.5% year over year and an +8.34% surprise against the Zacks Consensus Estimate of $11.27 billion, with EPS of $0.96 versus $0.97 a year ago and an EPS surprise of +17.07%.
OpenAI Rules Out 2026 IPO as Tanker Rates Hit Record Highs
OpenAI CEO Sam Altman confirmed the company will not go public in 2026, calling the timing "ill-advised" given current safety and alignment challenges, and has reportedly pushed advisers to target a $1 trillion valuation for any eventual offering. President Donald Trump rejected calls from tech leaders to slow AI model development, arguing restrictive guardrails would risk ceding America's technological lead to China, after proposals from Anthropic CEO Dario Amodei backed by Sam Altman and Elon Musk. Daily earnings for Very Large Crude Carriers on the benchmark Middle East-to-China route hit a record of nearly $800,000 following the biggest wave of attacks on Middle East shipping since the start of the U.S.-Iran conflict, while the U.S. Gulf-to-Asia run fetched offers at a record lump-sum fee of $29.5 million, roughly $15 per barrel before war-risk premiums. Novo Nordisk announced it will shorten its corporate name to Novo and update its logo, with CEO Mike Doustdar pushing to make the company leaner as it works to regain obesity-treatment market share against Eli Lilly, and will detail its updated strategy at a Capital Markets Day on September 21 in London.
UnitedHealth sells Optum Florida stake to TPG as CooperCompanies cuts guidance and Amgen slides
UnitedHealth has sold an interest in some of its Optum Health operations in Florida to private equity firm TPG, part of the health conglomerate's effort to recover from a collapse in profits last year. CFO Wayne DeVeydt told Bloomberg News that Optum Health margins will be around 2% this year, above prior expectations, and should rise to around 4% in 2027 and 6% the following year. Amgen fell more than 8%, its worst single-day decline since 2016, after Novartis announced a Phase 3 trial failure for the heart disease therapy pelacarsen, which it is developing with Ionis Pharmaceuticals; BMO Capital Markets downgraded Amgen to Market Perform from Market Outperform with a $450 price target. CooperCompanies dropped 13% after issuing fiscal 2026 guidance below consensus, with revenue of $4.229B-$4.252B versus the prior $4.285B-$4.321B and non-GAAP diluted EPS of $4.51-$4.55 versus $4.58-$4.66 previously, and said its board decided to keep CooperSurgical rather than sell it while raising its share buyback authorization to $3B from $2B. Novo Nordisk fell more than 1% premarket after Morgan Stanley downgraded the stock to Underweight from Equal-weight, citing the semaglutide patent cliff, and the S&P 500 Health Care Sector Index slipped more than 3.5% for the week.
Walgreens Closes 1,200 Stores as CVS Captures Suburban Pharmacy Market
Walgreens is closing roughly 1,200 of its approximately 8,500 U.S. locations through 2027, a retreat that is quietly handing suburban pharmacy customers to CVS. The closures accelerated after Walgreens completed a $10 billion sale to private equity firm Sycamore Partners in August 2025, taking the 124-year-old chain private for the first time; Mike Motz was named chief executive, replacing Tim Wentworth, who stays on as a director, and John Lederer became executive chairman. Company leadership has blamed shrinking pharmacy reimbursement rates, weaker retail traffic, and competition from Amazon Pharmacy for the decision, saying roughly a quarter of stores no longer fit the chain's strategy. CVS, which owns the pharmacy benefit manager Caremark, has not needed a marketing campaign to gain ground, and CVS and Walgreens together now handle nearly 40% of all U.S. retail prescription sales. CVS posted more than $106 billion in revenue and adjusted operating income of roughly $5.2 billion in its second-quarter 2026 results, up more than 35% from a year earlier, and raised its full-year 2026 adjusted earnings per share guidance to a range of $7.90 to $8.10. Walgreens has committed to continuing closures through 2027, with roughly 100 more expected before the end of 2026, while CVS is opening small-format stores, folding in leftover Rite Aid real estate, and leaning into GLP-1 access through new partnerships with Eli Lilly and Novo Nordisk.
Novo Nordisk's Wegovy Shows Promise in Pediatric Obesity Trial
Novo Nordisk's late-stage STEP Young trial found that 40.4% of children treated with semaglutide, the active ingredient in Wegovy, were no longer classified as having obesity after 68 weeks, compared with none receiving placebo. The trial met its primary endpoint, with semaglutide demonstrating a superior reduction in body mass index at week 68 versus placebo, though all participants also received lifestyle modifications including a reduced-calorie diet and increased physical activity. The result could expand the addressable market for Wegovy, as GLP-1 weight-loss drugs are not currently approved for children under 12 in the U.S., and a study published September 4 in the Pediatrics journal found that GLP-1 prescribing among children ages 8 to 11 with obesity and without diabetes increased roughly 310-fold from 2019 to 2026. The timing is significant as Novo seeks new growth drivers against Eli Lilly; in the REDEFINE 4 trial, Novo's next-generation candidate CagriSema produced 23.0% weight loss after 84 weeks versus 25.5% with Lilly's tirzepatide and failed the primary endpoint of non-inferiority. Hedge funds holding Novo Nordisk increased to 59 in Q2 from 55 in Q1, though positioning was mixed, and short interest rose around 15% to 33.83 million shares as of August 14.
UBS Upgrades Lockheed Martin, JPMorgan Upgrades Meta in Week of Analyst Calls
UBS upgraded Lockheed Martin to Buy from Neutral, arguing accelerating missile production, rising defense spending and growth beyond the F-35 franchise could drive earnings above Wall Street expectations. Analyst Gavin Parsons expects Lockheed revenue to grow at a compound annual rate of approximately 9% through 2028, with UBS projecting revenue of $81.05 billion in 2026, $88.48 billion in 2027 and $96.13 billion in 2028, the last about 6% above consensus, and adjusted earnings of $30.69 a share in 2026, $34.50 in 2027 and $39.34 in 2028, 12% above consensus. JPMorgan upgraded Meta Platforms to Overweight from Neutral with an $820 price target, implying a 25% increase from last close, citing upside from the launch of its AI assistant and frontier models. Morgan Stanley downgraded Novo Nordisk to Underweight from Equal-weight on semaglutide loss-of-exclusivity concerns, while Northland Securities upgraded Intel to Outperform from Market Perform with a $120 price target, and UBS cut NuScale Power to Sell from Neutral with a $6 price target, slashed from $10.
Morgan Stanley Downgrades Novo Nordisk to Underweight on Semaglutide Patent Cliff
Morgan Stanley downgraded Novo Nordisk to Underweight from Equal-weight, sending the shares down 1.23% in premarket trading and 2% in Copenhagen, while keeping a 250 DKK target that implies more than 10% downside. Analysts led by Thibault Boutherin wrote that the valuation does not entirely reflect subdued mid-term growth or the implications of the semaglutide patent cliff on Novo's terminal value. Semaglutide, the ingredient in Ozempic and Wegovy, accounted for 75% of sales in 2026 and is modeled at 59% in 2031, when loss of exclusivity starts to bite across Europe and the US. The bank sees the oral obesity franchise reaching $10 billion by 2031, which it says won't offset pricing and competitive headwinds, and forecasts 2% to 3% revenue and EBIT growth in 2027 and a 4% compound annual rate through 2030, against 4% revenue and 7% EBIT growth for European pharma generally. A Morgan Stanley survey of 200 primary care physicians pointed to share losses to Eli Lilly over the next 18 months, including retatrutide expected in 2027.
JPMorgan starts Hims & Hers at Neutral, $32 price target
JPMorgan initiated coverage of Hims & Hers Health with a Neutral rating and a December 2027 price target of $32, weighing the direct-to-consumer platform's rapid growth against execution risk in its shift to branded weight-loss drugs. Analyst Bryan Smilek noted the company has about 2.9 million subscribers across specialties including weight loss, women's health and hair loss, and is navigating a strategic transition in its GLP-1 business after saying in March it would prioritize branded, FDA-approved medications and stop advertising compounded GLP-1 offerings. Under a partnership with Novo Nordisk, Hims is said to have fulfilled more than 125,000 Wegovy shipments in the first six weeks of launch, and Smilek wrote that the Novo partnership should more than offset compounded GLP-1 headwinds, projecting 2026 GLP-1 revenue of $1.1 billion, up 46%, split between a decline in compounded sales and a surge in branded volumes. He pointed to a long runway, citing JPMorgan estimates that U.S. cash-pay GLP-1 users could reach more than 8 million by 2030 from about 2.8 million today, while the company targets 2030 revenue of more than $6.5 billion and adjusted EBITDA above $1.3 billion, aided by international expansion, new specialties such as peptides and AI-driven efficiency. Smilek said he is positive on Hims' vertical integration and leading brand scale and expansion across specialties and geographies, but wants to see execution on the branded GLP-1 transition, durable growth in newer specialties and margin expansion.
Eli Lilly Hits $1 Trillion Market Cap as 24/7 Wall St. Sets $1,220 Price Target
Eli Lilly has crossed into trillion-dollar territory, trading at $1,123.98 with a market capitalization of $1.002 trillion, and 24/7 Wall St. rates the stock a buy with a 12-month price target of $1,220.42, implying 8.58% upside at 90% confidence. The company's second-quarter 2026 revenue reached $22.974 billion, up 47.67% year over year, with earnings per share of $8.38 beating consensus by 27.27%, and management raised full-year revenue guidance to $85 billion to $87 billion. Mounjaro alone posted $9.94 billion, up 91% year over year, while the incretin franchise generated roughly $14.87 billion of the quarter's revenue. The bull case targets $1,381.62, a 22.92% gain, driven by retatrutide's planned BLA submission in the first quarter of 2027, the oral GLP-1 Foundayo's expansion to 36,000 prescribers, and the Medicare GLP-1 Bridge Program opening access for 20 million eligible Americans at $50 per month. The bear case takes shares to $1,045.34, a 7% decline, citing realized prices that fell 13% in the second quarter, $2.78 billion in acquired IPR&D charges, and net insider selling. Lilly's forward price-to-earnings ratio of 24 compares with 14 for Novo Nordisk, which grew quarterly revenue just 2.1%, and 16 for Merck, whose quarterly earnings shrank 19.3% year over year.
Novo Nordisk's Oral Wegovy Moves Closer to China Approval
Novo Nordisk has moved one step closer to bringing its oral Wegovy treatment to China after the country's drug regulator accepted the company's marketing application, opening a potential route into a market where GLP-1 weight-management sales could reach 30 billion yuan, or about $4.46 billion, within five to seven years, according to J.P. Morgan's head of China healthcare research, Yang Huang. The filing is an early regulatory milestone, not a final approval, and Novo has declined to provide a timeline for a decision. An oral version could help Novo reach patients who avoid injections, and the pill has already been approved in the United States and Britain, with a US launch earlier in 2026. However, Eli Lilly submitted its Chinese application for oral orforglipron at the end of 2025 and could launch as early as 2026, while Novo, Lilly, Pfizer, and Innovent Biologics already compete with injectable GLP-1 products in China. The 30-billion-yuan projection is an analyst forecast for the entire market, not an estimate of Wegovy's future sales, and the treatment's commercial contribution will depend on regulatory approval and competition in a crowded field.
Structure Therapeutics shares fall on obesity drug trial data
Structure Therapeutics shares fell on Tuesday after trial data for its lead obesity candidates, ACCG-2671 and aleniglipron, failed to lift investor expectations amid competition from established drugs by Novo Nordisk and Eli Lilly. In a Phase 1/2a single ascending dose trial, ACCG-2671, a dual amylin and calcitonin receptor agonist, caused about a 3% average weight reduction after a single dose in healthy volunteers without obesity, with a half-life of about six days supporting a potential once-weekly oral regimen. The company has started the multiple ascending dose portion of the trial, with topline data expected in the first half of 2027. For aleniglipron, data from the ACCESS open-label extension trial showed that patients on the 180 mg dose lost up to 16% of their weight after 72 weeks with no plateau, while enrollment continues in the ACCOMPLISH-1 and ACCOMPLISH-2 Phase 3 studies, with topline data expected in the second half of 2028. In comparison, FDA-approved oral weight loss therapies from Novo Nordisk and Eli Lilly have achieved average weight loss of up to 14% and 11% over 64 and 72 weeks, respectively.
Novo Nordisk halts two heart drug trials after data review
Novo Nordisk has halted two late-stage trials of its experimental heart drug ziltivekimab after an independent data monitoring committee found a low likelihood of success, adding to recent pipeline setbacks. The decision follows July results showing ziltivekimab failed to reduce major cardiovascular events compared with placebo in the Phase 3 ZEUS trial. However, another trial in patients recovering from a heart attack will continue, with results expected in H1 2027. The setback is significant as Novo Nordisk had sought to expand into cardiovascular disease to reduce reliance on its obesity and diabetes medicines. Shares traded about 1.55% lower in premarket trading on Tuesday.
Novo Nordisk Falls as Childhood Win Offsets Trial Cancellations
Novo Nordisk (NYSE:NVO) traded at $46.60 Monday, down nearly 2%, as two clinical signals pulled the investment case in opposite directions. Reuters reported that Novo stopped two ziltivekimab heart-failure trials, punching another hole in its diversification strategy. But semaglutide simultaneously opened the door to a younger obesity market. The STEP Young trial enrolled 165 children aged 6 to under 12; after 68 weeks, 40.4% of semaglutide patients dropped below the obesity threshold, compared with zero placebo recipients, assuming full adherence. Both groups received diet and exercise support, more than 85% entered with severe obesity, and Novo found no new concerns involving growth or puberty. Novo generated DKK33.39 billion of adjusted second-quarter operating profit from DKK78.49 billion of revenue, producing a 42.5% margin. At $46.60, the stock sits 55.98% below its $105.85 GF Value, revealing how much pessimism is already baked into the price.
Novo Nordisk Buys Back 17.3 Million B Shares Under DKK 15 Billion Programme
Novo Nordisk has repurchased 17,275,000 B shares under its share repurchase programme initiated on 6 May 2026, part of an overall programme of up to DKK 15 billion running from 4 February 2026. The latest transactions, announced on 7 September 2026, cover purchases made between 31 August and 4 September, bringing the total transaction value under the May programme to DKK 5,221,774,293. Since 4 February, the company has repurchased 32,034,179 B shares at an average price of DKK 281.63 per share, for a total of DKK 9,021,774,283. Novo Nordisk now holds 46,074,876 B shares as treasury shares, representing 1.0% of its share capital.
Lilly Launches Foundayo in UK, First European Market
Eli Lilly and Company has launched Foundayo in the United Kingdom, making Britain the first European country where its oral treatment for weight management and type 2 diabetes is available. The pill, known chemically as orforglipron, became available through private prescription after the UK medicines regulator authorised it on August 10. Lilly expects Foundayo to cost between £100 and £120 per month through private providers, compared with approximately £330 for a month's supply of its Mounjaro injection. However, access through England's state-run National Health Service will depend on a separate review by the National Institute for Health and Care Excellence, which has requested additional information and has not scheduled a second meeting. Foundayo remains under review in the European Union, and it is the second GLP-1 tablet launched in the UK, following Novo Nordisk's Wegovy pill.
Novo Nordisk Launches Wegovy Pill in Germany, First in EU
Novo Nordisk A/S has launched its Wegovy weight-loss pill in Germany, making it the first country in the European Union where the oral version of the drug is available. Germany is the EU's largest pharmaceutical market, so the launch is an important step for Novo as it works to strengthen its position in the growing obesity-drug market. The pill contains semaglutide, the same active ingredient used in Novo's Wegovy injection and Ozempic. Prices will vary depending on the dosage and are expected to be similar to the injectable version of Wegovy, which currently sells at pharmacy retail prices of around €170 to €280 in Germany. The launch comes as Novo faces growing competition from Eli Lilly. Novo Nordisk A/S said in August that its Wegovy pill had captured around 90% of the oral obesity market, despite competition from Lilly. Lilly's Foundayo has already launched in the UK and is expected to enter other major markets in 2027.
Novo Nordisk Launches Wegovy Pill in Germany, Trades 58% Below GF Value
Novo Nordisk has launched its oral Wegovy pill in Germany, the European Union's largest pharmaceutical market, marking the first availability of the pill in the EU. The company's shares rose about 0.5% to $45.545 on Tuesday. Novo expects the pill to be priced similarly to Wegovy injections, which currently cost between 170 and 280 euros in Germany, and believes pills could capture more than one-third of GLP-1 use by 2030. However, the company faces competition from Eli Lilly, which has launched its Foundayo pill in Britain and is targeting approval in over 40 markets. Novo's stock trades 57.88% below its GF Value estimate of $108.13, and the durability of its 90% share of the oral obesity market will be tested by reimbursement, repeat prescriptions, and Lilly's expansion.
FDA Approves Eli Lilly's Mounjaro to Cut Cardiovascular Risk in Diabetes
The FDA has approved Eli Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type II diabetes who are at high risk for major adverse cardiovascular events, including cardiovascular death, non-fatal heart attack, and non-fatal stroke. The approval was based on the phase III SURPASS-CVOT study, which enrolled 13,299 adults and compared Mounjaro with Lilly's Trulicity, showing an 8% lower rate of major adverse cardiovascular events with a hazard ratio of 0.92, though superiority was not established. This expanded indication strengthens Lilly's position in the cardiometabolic market and broadens the eligible patient pool, potentially driving further prescription growth. Mounjaro generated worldwide revenues of $18.6 billion in the first half of 2026, up 106% year over year, and the new label could provide an additional sales catalyst. The approval also narrows the indication gap with Novo Nordisk's Ozempic, which retains an edge in cardiovascular and kidney-related indications, while Mounjaro's momentum contrasts with Ozempic's adjusted first-half 2026 sales of $9.21 billion, down 2% at constant exchange rates.
Novo Nordisk Bets on CagriSema to Close Obesity Gap with Eli Lilly
Novo Nordisk is counting on its next-generation obesity drug CagriSema to close the competitive gap with Eli Lilly, having filed for U.S. approval with an FDA decision expected in the fourth quarter of 2026. In the phase III REDEFINE 1 study, CagriSema achieved a mean weight loss of 22.7% after 68 weeks, compared with 16.1% for Wegovy, but in the head-to-head REDEFINE 4 trial it delivered 23% weight loss versus Zepbound's 25.5%, failing to show non-inferiority. The company's need for new growth drivers is pressing as first-half 2026 adjusted sales rose only 2% at constant exchange rates, while Eli Lilly's Mounjaro and Zepbound generated $18.6 billion and $9.1 billion in first-half sales, up 106% and 60% respectively. Novo Nordisk is also testing a higher-dose combination of cagrilintide 2.4 mg with Wegovy HD (semaglutide 7.2 mg) in a phase III study planned for the second half of 2026, and results from the REDEFINE 11 study are expected in the first half of 2027. The company faces additional competition from Viking Therapeutics and Structure Therapeutics, which are advancing their own GLP-1-based obesity therapies.
Novo Nordisk has provided an update on its share repurchase programme, reporting transactions made between 24 and 28 August 2026. Under the programme initiated on 6 May 2026, the company repurchased 1,050,000 B shares at an average price of approximately DKK 302.09, totaling about DKK 317.2 million. This brings the accumulated repurchases under this programme to 16,220,000 B shares worth DKK 4,907,673,815. The programme is part of a larger buyback of up to DKK 15 billion over 12 months starting 4 February 2026, under which the company has so far repurchased 30,979,179 B shares at an average price of DKK 281.08, totaling DKK 8,707,673,805. Novo Nordisk now holds 45,019,876 B shares as treasury shares, representing 1.0% of its share capital.
Denmark's Ministry of Taxation and Economic Growth on the 27th raised its forecast for gross domestic product (GDP) growth in 2026 to 3.7%. The previous forecast in May was 2.7%. Minister for Taxation and Economic Growth Jakob Engel-Schmidt said in a statement that growth is mainly driven by expanding pharmaceutical exports, most of which are related to the U.S. market. The global market for weight-loss drugs is expanding, and Novo Nordisk launched its new oral drug, Wegovy, earlier this year. The ministry also raised its 2027 GDP growth forecast from 1.6% to 1.8%. The central bank had expected growth of 1.8% for both 2026 and 2027 in March.
Eli Lilly Study Shows Zepbound Cuts Healthcare Costs
Eli Lilly has released a real-world study suggesting that its obesity drug Zepbound may offset a significant portion of its cost by reducing other healthcare spending, bolstering its case for broader coverage. The study, which analyzed de-identified U.S. insurance claims from more than 15,000 adults over age 55, found that patients who remained on Zepbound had average monthly healthcare costs up to 15% lower after six months and 38% lower after 12 months, excluding the drug's price. Lilly estimates savings reached as much as $181 per patient by six months, compared with a roughly $195 monthly treatment cost under Medicare's GLP-1 Bridge program, suggesting other savings could offset much of the government's drug expenditure. The findings strengthen Lilly's competitive position against Novo Nordisk's Wegovy, which is included in the same Medicare program, and could influence coverage decisions by Medicare, employers, and other payers.
Germany